RenovoRx Revenue Jumps 28 Percent in Q2

RenovoRx (RNXT) reported Q2 2025 revenue of $422,000, significantly beating analyst estimates by 28% and marking the second full quarter of RenovoCath commercial sales. While GAAP net loss widened to $2.9 million, the company's loss per share of ($0.08) was better than expected. This quarter highlighted strong commercial momentum, with approved cancer centers for RenovoCath expanding from five to thirteen, and early repeat purchases indicating growing adoption. With $12.3 million in cash, RenovoRx is positioned to fund continued commercial expansion and its pivotal Phase III TIGeR-PaC trial, underscoring emerging traction for its targeted cancer therapy delivery platform.

Analysis

RenovoRx (RNXT) demonstrated significant early commercial momentum in its Q2 2025 results, with revenue of $422,000 decisively beating analyst estimates by 28.0% in only its second full quarter of RenovoCath sales. This top-line performance is supported by strong underlying adoption metrics, as the number of cancer centers approved to purchase the device grew from five to thirteen, with four of these centers already making repeat purchases. While the GAAP net loss widened to $2.9 million from $2.4 million year-over-year, this was attributed primarily to a non-cash warrant liability adjustment, and the GAAP loss per share improved to ($0.08) from ($0.10) in the prior year, also beating estimates. The company's financial position has been strengthened, with cash increasing to $12.3 million, which management states is sufficient to fund the ongoing commercial build-out and the pivotal Phase III TIGeR-PaC trial. The continuation of this trial, as recommended by an independent monitoring committee, is a critical de-risking event, reinforcing the potential of its targeted therapy platform even as the company withholds detailed interim efficacy data to maintain trial integrity for regulatory submission.

Key Decisions for Investors

• Investors should view RenovoRx as an early-stage commercialization story where the significant revenue beat and tripling of approved cancer centers signal strong initial market adoption, warranting consideration for portfolios with a high-risk tolerance for pre-profitability med-tech.
• The primary long-term value driver remains the pivotal Phase III TIGeR-PaC trial; closely monitor updates on patient enrollment, event milestones, and the eventual final data readout, as positive results are essential for unlocking the estimated $400 million peak U.S. market.
• Despite management's confidence in the current cash sufficiency, it is prudent to track quarterly revenue growth and operating expenses to validate the path to profitability and assess the execution of the new sales leadership in converting the pipeline of 18 additional trial sites into commercial customers.